| |
Newsroom /
Science and Research
/
Science and Research
/
Choroidal Neovascularization Therapeutics
Choroidal Neovascularization Therapeutics
Choroidal Neovascularization Therapeutics Market is Forecast to Show high Growth until 2017, The report identifies the key trends shaping and driving the global CNV market.
Hyderabad,
AP,
India
(prbd.net)
15/06/2011
GlobalData forecasts the global Choroidal Neovascularization (CNV) therapeutics market to grow at 6.8%
annually for the next seven years, to reach $4.19 billion by 2017. It was valued at $2.6 billion in 2010. This significant growth is primarily attributed to an increase in treatment rates and a high annual cost of
therapy for the approved market drugs. The market has experienced tremendous growth due to the
introduction of anti-VEGF (Vascular Endothelial Growth Factor) drugs for the treatment of CNV.
GlobalData’s analysis indicates that the current competition in the CNV therapeutics market is strong and the available treatment options have been successful in meeting the market need. The current marketed products are successful in treating the underlying cause of the disease. The extent of unmet need in the CNV therapeutics market is considered to be low. The current market drugs include Lucentis
(ranibizumab), approved for CNV associated with wet age related macular degeneration (AMD), Visudyne (verteporfin), approved for CNV associated with wet AMD, presumed ocular histoplasmosis and pathologic myopia, and Macugen (pegaptanib), approved for CNV associated with wet AMD. Apart from these there is Avastin (bevacizumab), which is not approved for CNV (off-label) and is in Phase III of
clinical development, has gradually captured a major share of the market.
For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Choroidal-Neovascularization-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017
GlobalData found that there are 38 products in different stages of development. In Phase III trials of
clinical development, VEGF-trap eye is being tried for CNV associated with AMD, Lucentis for CNV
associated with pathologic myopia and Avastin for both CNV associated with pathological myopia and
AMD. VEGF-trap eye can reduce the dose frequency and has potential in the CNV therapeutics market.
These products are expected to meet some of the unmet needs in the market and will provide physicians with a wider choice in treating CNV. Apart from this, Avastin which is currently used as an off-label drug will intensify the market competition once approved. In summary, the global CNV therapeutics market is heading towards a highly competitive landscape.
GlobalData, the industry analysis specialist, has released its new report, “Choroidal Neovascularization
Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source
of information and analysis on the global choroidal neovascularization (CNV) market. The report identifies the key trends shaping and driving the global CNV market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market
positioning of the current market leaders. Most importantly, the report provides valuable insights on the
pipeline products within the global CNV sector. This report is built using data and information sourced
from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Choroidal-Neovascularization-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017
Visit our report store: http://www.globaldata.com
For more details contact:
pressreleases@globaldata.com
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782
About
GlobalData is a global market intelligence services company providing information research and analysis products and services.
|